Cryptococcal fungemia and Mycobacterium haemophilum cellulitis in a patient receiving ruxolitinib: a case report and literature review

BACKGROUND: Ruxolitinib is a novel oral Janus kinase inhibitor that is used for treatment of myeloproliferative diseases. It exhibits potent anti-inflammatory and immunosuppressive effects, and may increase the risk of opportunistic infections. Here, we report a rare case of Cryptococcus neoformans...

Descripción completa

Detalles Bibliográficos
Autores principales: Sayabovorn, Naruemit, Chongtrakool, Piriyaporn, Chayakulkeeree, Methee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792301/
https://www.ncbi.nlm.nih.gov/pubmed/33413168
http://dx.doi.org/10.1186/s12879-020-05703-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792301/
https://www.ncbi.nlm.nih.gov/pubmed/33413168
http://dx.doi.org/10.1186/s12879-020-05703-2

Ejemplares similares